Teleflex

Teleflex (NYSE: TFX) + shares took a hit today despite fourth-quarter results that came in ahead of the consensus forecast.

Shares of TFX fell 4.6% at $239.36 apiece in midday trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose slightly.

The Wayne, Pennsylvania-based company posted profits of $31.1 million in the quarter. That amounts to 66¢ per share on sales of $773.9 million for the three months ended Dec. 31, 2023. Teleflex recorded a 60.4% bottom-line slide on sales growth of 2.1%.

Adjusted to exclude one-time items, earnings per share totaled $3.38, landing 12¢ ahead of Wall Street projections. Sales also beat the forecasts as analysts anticipated $768.7 million in revenue.

Teleflex reported significant growth in its OEM (12.1%), Interventional (8.5%) and Interventional Urology (4.3%) segments.

“We demonstrat…

[Image from Teleflex]Teleflex (NYSE: TFX) + announced today that it enrolled the first patient in a clinical registry evaluating its Manta vascular closure device (VCD).

The company aims for the registry to examine and collect data on outcomes of contemporary on-label use of Manta in standard of care transcatheter aortic valve replacement (TAVR) procedures. It includes appropriate patient selection and proper vascular access.

Wayne, Pennsylvania-based Teleflex offers Manta as the first commercially available biomechanical VCD for large-bore femoral arterial access site closure. The technology offers an alternative to cut-down and suture-mediated closure in large-bore procedures.

Since its first implantation in 2014, Manta received CE mark in 2016 and FDA approval in 2019. Teleflex said studies of Manta reached over 10,000 patients, with 150,000 units sold globally.

The ACCESS-MANTA registry aims to enroll at…

Teleflex (NYSE: TFX) + shares received a big boost today on third-quarter results that came in ahead of the consensus forecast.

Shares of TFX rose more than 10% to $206.33 apiece in mid-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — ticked up slightly.

The Wayne, Pennsylvania-based company posted profits of $137.1 million. That amounts to earnings of $2.90 per share on sales of $746.4 million for the three months ended Oct. 1, 2023. Teleflex posted a 34.6% bottom-line gain on sales growth of 8.7%.

Adjusted to exclude one-time items, earnings per share of $3.64 came in 37¢ ahead of Wall Street expectations. Sales also topped consensus forecasts of $733.56 million.

Teleflex Chair, President and CEO Liam Kelly cited stability in surgical procedures as one driver of the company’s performance. Kelly also noted st…

Teleflex (NYSE: TFX) + announced today that it released its Arrow ErgoPack complete kits with hemodialysis and larbe bore catheters in the U.S.

Wayne, Pennsylvania-based Teleflex launched this update to streamline insertion workflow for clinicians. The company also says it provides more options to suit their particular needs.

Get the full story at our sister site, Medical Tubing & Extrusion.

Teleflex (NYSE: TFX) + shares fell this morning despite strong second-quarter results and an increased full-year guidance.

Shares of TFX dipped 2.8% at $241.75 apiece in mid-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — fell 0.8%.

The Wayne, Pennsylvania-based company posted profits of $111.3 million in the quarter. That amounts to $2.23 per share on sales of $743.3 million for the three months ended July 2, 2023.

Teleflex recorded a 5.5% bottom-line gain on sales growth of 5.5%.

Adjusted to exclude one-time items, earnings per share came in 20¢ ahead of Wall Street expectations of $3.21. Sales topped analysts’ forecasts too as they projected $729.9 million in revenue.

Teleflex’s OEM business reported the strongest growth, improving by 20.2% year-over-year. Vascular Access (6%), Interventional …

Teleflex (NYSE: TFX) + announced today that it completed patient enrollment in its prospective multicenter Ringer PTCA study.

Ringer PTCA is one of two clinical studies evaluating Teleflex’s novel Ringer perfusion balloon catheter. The trial enrolled patients across seven leading complex percutaneous coronary intervention (PCI) centers in the U.S. and Canada. Dr. Kathleen Kearney of the University of Washington leads the trial.

Kearney said in a news release that Ringer’s availability “is much anticipated by the interventional cardiology community.” She added that completed enrollment in the trial marks “a big step” toward that milestone.

Wayne, Pennsylvania-based Teleflex said the study employed Ringer in selected coronary intervention patients who could benefit from continued perfusion during coronary balloon inflations.

Parallel to Ringer PTCA, Teleflex …

The FDA today designated Teleflex’s recall of its Arrow Endurance extended dwell peripheral catheter system as Class I, the most serious type of medical device recall.

The recall involved 262,016 devices distributed from October 26, 2018, to May 10, 2023, according to the FDA.

Teleflex and its Arrow International subsidiary have reported 83 complaints related to this issue. There are reports of 18 injuries but no deaths.

The Endurance system provides short-term access to a person’s peripheral vascular system, enabling health providers to sample blood, monitor blood pressure, or administer fluids, blood, and blood products.

Teleflex initiated a recall on May 19 after receiving reports of catheter separation or leakage. If the catheter separates while in a blood vessel, the catheter fragments could be left in the bloodstream and may migrate to other places in the body. The situation could cause a person to experience a blockage of blood …

Teleflex this week announced a global recall of affected batches of its Rüsch endotracheal tube products.

The Wayne, Pennsylvania-based company is recalling certain devices due to reports of disconnection of the 15mm connector from the endotracheal tube (ET tube) for the affected products. There is a possibility of oxygen desaturation, and in the event, any immediate or long-term health consequences depend on the degree and duration of desaturation.

Initial investigations have identified that the disconnection results from the intermittent cross-contamination of the 15mm connector with trace amounts of silicone oil. Although this does increase the lubricity of the connection, this does not present additional clinical risks, according to the company.

Where patients are undergoing mechanical ventilation in either the operating room or critical care settings, the ventilation devices to which the affected devices are connected are designed to alarm immediate…